A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

PHASE2CompletedINTERVENTIONAL
Enrollment

295

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

November 30, 2013

Conditions
Attention-Deficit/Hyperactivity DisorderADHD
Interventions
DRUG

TD-9855

Once daily

DRUG

TD-9855

Once daily

DRUG

Placebo

Once daily

Trial Locations (17)

10016

Adult ADHD Program, New York

30080

Carman Research, Smyrna

32256

Clinical Neuroscience Solutions, Inc., Jacksonville

33407

Janus Ctr. for Psychiatric Research, Palm Beach

34201

Florida Clinical Research Center, LLC, Bradenton

Florida Clinical Research Center, Maitland

38119

CNS Healthcare of Memphis, Memphis

63304

Midwest Research Group, Saint Charles

66211

Psychiatric Associates, Overland Park

73103

IPS Research, Oklahoma City

78731

FutureSearch Clinical Trials, Austin

84105

Psychiatric & Behavioral Solutions, Salt Lake City

84106

Lifetree Clinical Research, LC, Salt Lake City

89128

Ctr. for Psychiatry & Behavioral Med., Las Vegas

97210

Summit Research Network, Portland

98104

Summit Research Network (Seattle), LLC, Seattle

02865

Lincoln Research, Lincoln

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY